Withdrawn trial aimed to halt rare cancer in High-Risk families
NCT ID NCT06654050
Summary
This study aimed to test if an oral drug called APG-115 could stop or slow the growth of early-stage mesothelioma in people with a specific inherited gene mutation (BAP1). Participants would have taken the drug at home in repeating cycles while undergoing regular scans and biopsies to check its effect. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.